Covered recipient · General Payments record
DAVID M BROWN
Allopathic & Osteopathic Physicians Ophthalmology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$159,751.81
75 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $139,411.00 | 25 |
| Travel and Lodging | $16,277.51 | 5 |
| Food and Beverage | $2,063.30 | 44 |
| Honoraria | $2,000.00 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| TOPCON HEALTHCARE, INC. | $95,063.14 | 11 |
| Optos plc | $46,277.51 | 10 |
| Ocular Therapeutix, Inc. | $4,413.62 | 5 |
| Apellis Pharmaceuticals, Inc. | $4,205.33 | 11 |
| Regeneron Pharmaceuticals, Inc. | $2,242.94 | 3 |
| Apotex Inc. | $2,000.00 | 1 |
| Boehringer Ingelheim International GmbH | $1,900.00 | 2 |
| Harrow Eye, LLC | $1,528.97 | 2 |
| Kowa Research Institute, Inc. | $1,200.00 | 1 |
| Regeneron Healthcare Solutions, Inc. | $398.08 | 15 |
| Carl Zeiss Meditec USA, Inc. | $238.67 | 4 |
| Astellas Pharma US Inc | $162.48 | 5 |
| ABBVIE INC. | $73.36 | 3 |
| Genentech USA, Inc. | $47.71 | 2 |
Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID M BROWN
NPI 1548368509 · CMS profile ID 342787
Allopathic & Osteopathic Physicians / Ophthalmology
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1548368509?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID M BROWN, NPI 1548368509, CMS profile ID 342787. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548368509?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). DAVID M BROWN, NPI 1548368509, CMS profile ID 342787. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548368509?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- DAVID M BROWN, NPI 1548368509, CMS profile ID 342787, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1548368509?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
75 matching records · $159,751.81 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–75 of 75.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $26.89 | 05/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212879893 | CMS |
| Apotex Inc. | $2,000.00 | 05/14/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1183027079 | CMS |
| Regeneron Healthcare Solutions, Inc. | $6.28 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212879891 | CMS |
| Genentech USA, Inc. | $24.76 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211507272 | CMS |
| Topcon Healthcare, Inc. | $38.09 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249732693 | CMS |
| Topcon Healthcare, Inc. | $25.05 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249732695 | CMS |
| Carl Zeiss Meditec USA, Inc. | $69.65 | 04/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249351313 | CMS |
| Apellis Pharmaceuticals, Inc. | $25.25 | 04/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253192548 | CMS |
| Carl Zeiss Meditec USA, Inc. | $9.84 | 04/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249351317 | CMS |
| Apellis Pharmaceuticals, Inc. | $10.89 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253192544 | CMS |
| Apellis Pharmaceuticals, Inc. | $21.82 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253192546 | CMS |
| Astellas Pharma US Inc | $33.98 | 03/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238764186 | CMS |
| Regeneron Pharmaceuticals, Inc. | $1,105.00 | 03/21/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213235957 | CMS |
| Regeneron Healthcare Solutions, Inc. | $26.20 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212879889 | CMS |
| Genentech USA, Inc. | $22.95 | 03/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211507270 | CMS |
| Astellas Pharma US Inc | $34.68 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238753990 | CMS |
| Regeneron Healthcare Solutions, Inc. | $25.12 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212879887 | CMS |
| Apellis Pharmaceuticals, Inc. | $20.77 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253192542 | CMS |
| Boehringer Ingelheim International GmbH | $950.00 | 01/17/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215868713 | CMS |
| Boehringer Ingelheim International GmbH | $950.00 | 01/17/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215868720 | CMS |
| Regeneron Healthcare Solutions, Inc. | $33.95 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212879885 | CMS |
| Apellis Pharmaceuticals, Inc. | $87.62 | 01/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253192540 | CMS |
| TOPCON HEALTHCARE, INC. | $15,000.00 | 01/13/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249731635 | CMS |
| Kowa Research Institute, Inc. | $1,200.00 | 01/10/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184285923 | CMS |
| Ocular Therapeutix, Inc. | $1,000.00 | 01/08/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250227697 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $9,705.02 | 2 |
| PY2025 | Principal investigator | $19,513,460.01 | 1,699 |
| PY2024 | Recipient | $1,750.00 | 1 |
| PY2024 | Principal investigator | $11,800,547.70 | 828 |
| PY2023 | Recipient | $12,927.43 | 3 |
| PY2023 | Principal investigator | $5,064,965.90 | 455 |
| PY2022 | Recipient | $22,135.52 | 8 |
| PY2022 | Principal investigator | $4,336,658.95 | 295 |
| PY2021 | Recipient | $2,434.27 | 3 |
| PY2021 | Principal investigator | $4,544,492.39 | 287 |
| PY2020 | Recipient | $1,375.85 | 1 |
| PY2020 | Principal investigator | $4,038,411.76 | 213 |
| PY2019 | Recipient | $3,617.25 | 3 |
| PY2019 | Principal investigator | $1,852,708.30 | 105 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
1,701 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Roche TCRC, Inc. | $45,341.00 | 12/31/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644717 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $431.65 | 12/25/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184115875 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,956.95 | 12/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184279832 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $49.56 | 12/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184279836 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,568.00 | 12/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1190311247 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,893.00 | 12/17/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644636 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $23,300.00 | 12/17/2025 | Non-covered Recipient Entity Retina Consultants Of Houston | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226100421 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,623.00 | 12/17/2025 | Non-covered Recipient Entity Retina Consultants Of Houston | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226100429 |
| Principal investigator 1 | Roche TCRC, Inc. | $10,170.00 | 12/15/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644649 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,694.25 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272721 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,768.50 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272723 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,694.25 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272725 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272745 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272747 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272749 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $101.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272755 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $78.01 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272757 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $101.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272759 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272761 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272763 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272765 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272767 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272769 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272771 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272773 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272777 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $78.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272779 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184272781 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272797 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272799 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272801 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272803 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272807 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272809 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272811 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272813 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272815 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272817 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272819 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272821 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272823 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272825 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272829 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272831 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272835 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272837 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272839 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272841 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272843 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272845 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272847 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272851 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272853 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272855 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272857 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272859 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272861 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272863 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272865 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272867 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272869 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272873 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272875 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272877 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272879 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272881 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272883 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272885 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272887 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272889 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272891 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272897 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272899 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272901 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272903 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272905 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184272907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273019 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273021 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273023 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273025 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273029 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273031 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273033 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273035 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273037 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273039 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273041 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273043 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273045 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273047 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273051 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273053 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273055 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273057 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273059 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273061 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273063 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273065 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273067 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273069 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273073 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273075 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273077 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273079 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273081 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273083 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273085 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273087 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273089 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273091 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,000.00 | 12/10/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644670 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 12/05/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242368741 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 12/05/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242368743 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 12/05/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242368745 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,715.00 | 12/05/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644617 |
| Principal investigator 1 | Roche TCRC, Inc. | $18,807.00 | 12/05/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644626 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,325.50 | 12/05/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644630 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,139.60 | 12/05/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644641 |
| Principal investigator 1 | Roche TCRC, Inc. | $16,623.00 | 12/05/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644644 |
| Principal investigator 1 | Roche TCRC, Inc. | $13,505.00 | 12/05/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644651 |
| Principal investigator 1 | Roche TCRC, Inc. | $520.00 | 12/05/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644665 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 12/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268235 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $115.00 | 12/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268237 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 12/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268239 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.00 | 12/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268241 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 12/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268243 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 12/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268245 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $101.00 | 12/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268247 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $78.00 | 12/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268249 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268251 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $14.00 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211644406 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,000.00 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211644408 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $14.00 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211644411 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,093.00 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211644417 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,093.00 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211644421 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,500.00 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211644423 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $14.00 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211644426 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $269.00 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211644429 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $500.00 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211644433 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,067.00 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211644438 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,067.00 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211644442 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $581.00 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211644446 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,917.35 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267211 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,120.85 | 12/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267213 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,531.60 | 12/01/2025 | Non-covered Recipient Entity RETINA GROUP INC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184267241 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184266561 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.00 | 11/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184266563 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,196.81 | 11/24/2025 | Non-covered Recipient Entity Rctx-Texas Medical Center Retina Center | A First-in Human trial to study safety and tolerability of single rising intravitreal dOses (open label, non-randomized, uncontrolled) and in addition the early biological response of multiple intravitReal dosing (single-masked, raNdomized, sham-controlle | No dispute reported | 06/30/2026 | 1220803118 |
| Principal investigator 1 | Genentech, Inc. | $1,743.00 | 11/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644337 |
| Principal investigator 1 | Genentech, Inc. | $65.00 | 11/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644344 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $521.00 | 11/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184261607 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 11/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184261609 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.00 | 11/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184261611 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 11/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184261613 |
| Principal investigator 1 | Genentech, Inc. | $114.00 | 11/14/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644319 |
| Principal investigator 1 | Roche TCRC, Inc. | $17,832.00 | 11/14/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644610 |
| Principal investigator 1 | Roche TCRC, Inc. | $5,780.00 | 11/14/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644622 |
| Principal investigator 1 | Genentech, Inc. | $1,796.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644341 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259771 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259773 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259775 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259777 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259779 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259781 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259783 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,052.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259785 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259787 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259789 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259791 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259793 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259795 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259797 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184259799 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity Retina Consultants of Houston, PLLC | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250363726 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 11/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184257637 |
| Principal investigator 1 | Genentech, Inc. | $14,936.00 | 11/05/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644327 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 10/30/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184256157 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 10/30/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184256159 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254991 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254993 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254995 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254997 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254999 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255001 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255003 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255005 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255007 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255009 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,052.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255011 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255013 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255015 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255017 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255019 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255021 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255023 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255025 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255027 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255029 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255031 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255033 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 10/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255035 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $59.50 | 10/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | Natural History Study in Diabetic Retinopathy | No dispute reported | 06/30/2026 | 1211644403 |
| Principal investigator 1 | Roche TCRC, Inc. | $4,263.00 | 10/23/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644721 |
| Principal investigator 1 | Roche TCRC, Inc. | $8,866.90 | 10/20/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644614 |
| Principal investigator 1 | Roche TCRC, Inc. | $390.00 | 10/20/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644655 |
| Principal investigator 1 | Genentech, Inc. | $1,796.00 | 10/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644315 |
| Principal investigator 1 | Roche TCRC, Inc. | $398.00 | 10/17/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644661 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184251073 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184251075 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184251077 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184251079 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184251081 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184251083 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184251085 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184251087 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184251089 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $61.92 | 10/15/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184250271 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $49.56 | 10/15/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184250273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $81.90 | 10/15/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184250275 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 10/10/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363511 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 10/10/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363513 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 10/10/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363515 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 10/10/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363517 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 10/10/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363519 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 10/10/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363521 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 10/10/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242363523 |
| Principal investigator 1 | Janssen Research & Development, LLC | $792.00 | 10/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1175401557 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/09/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249462 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/09/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249464 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184247954 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184247958 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184247962 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184247964 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184247966 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184247970 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184247972 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 10/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184246055 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 10/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184246057 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246089 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,532.25 | 10/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246091 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246093 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246095 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246097 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246099 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246101 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246103 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243891 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243893 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243895 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243897 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243899 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243901 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243903 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243905 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243909 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243911 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243913 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243915 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,052.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243917 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243923 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243925 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243929 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243931 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243933 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184243935 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242335 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242337 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242339 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,531.60 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242341 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242343 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242345 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.00 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242347 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242349 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.00 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242351 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242353 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242355 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242357 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,531.60 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242359 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184242361 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,835.80 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184242363 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,768.50 | 09/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184242365 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $276.10 | 09/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242359022 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 09/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242359108 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 09/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242359110 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 09/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242359112 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/22/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241462 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/22/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241464 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/22/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241466 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/22/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241468 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/22/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241470 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/22/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241472 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/22/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241474 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/22/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241476 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238592 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238594 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238596 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238598 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238600 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,917.35 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238602 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238604 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238606 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238608 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238610 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238612 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238614 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $88.64 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238806 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $73.72 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238808 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.70 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238810 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $81.88 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238812 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.22 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238814 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $91.42 | 09/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184238816 |
| Principal investigator 1 | Roche TCRC, Inc. | $7,970.00 | 09/16/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644592 |
| Principal investigator 1 | Roche TCRC, Inc. | $260.00 | 09/16/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644597 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,972.10 | 09/16/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644604 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,566.00 | 09/15/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644601 |
| Principal investigator 1 | Genentech, Inc. | $130.00 | 09/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644309 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184236315 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184236317 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184236319 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184236321 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184236323 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 09/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184236325 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 09/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184236327 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 09/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184236329 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 09/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184236331 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184236021 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184236023 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 09/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184235675 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $600.00 | 09/08/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411432 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $418.50 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235431 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235433 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235435 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235437 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235439 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235441 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235443 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235445 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235447 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235449 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235451 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235453 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235455 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235459 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235461 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235463 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235465 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235467 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235471 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235473 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235475 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235477 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $418.50 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235479 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235481 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235483 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235485 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235487 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235489 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235491 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235493 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235495 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235497 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235499 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235501 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235503 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235507 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235509 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235511 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235513 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235515 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235517 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235519 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235527 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235529 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235531 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235535 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235537 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235539 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235541 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $418.50 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235545 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,000.00 | 09/03/2025 | Non-covered Recipient Entity Retina Consultants of Houston, PLLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234185512 |
| Principal investigator 1 | Astellas Pharma Global Development | $100.00 | 09/03/2025 | Non-covered Recipient Entity Retina Consultants of Houston, PLLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234185516 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/03/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184234517 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,605.25 | 08/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184232658 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,679.85 | 08/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184232660 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,882.35 | 08/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184232662 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,060.20 | 08/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184232680 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $73.96 | 08/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184232684 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184232832 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 08/25/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175401562 |
| Principal investigator 1 | Genentech, Inc. | $2,024.00 | 08/22/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644294 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,850.00 | 08/21/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409496 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $156.60 | 08/14/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409236 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $156.60 | 08/14/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409258 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $70.20 | 08/14/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409334 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $357.75 | 08/14/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409362 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $357.75 | 08/14/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409374 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $357.75 | 08/14/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409422 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $156.60 | 08/14/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409432 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $40.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants of Houston, PLLC | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250363632 |
| Principal investigator 1 | Astellas Pharma Global Development | $9,000.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants of Houston, PLLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234185514 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,000.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409206 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409224 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.45 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409240 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $371.25 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409248 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $324.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409282 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $405.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409296 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $67.50 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409308 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,484.89 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409316 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,000.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409318 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $324.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409322 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $67.50 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409328 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $147.15 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409336 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,131.19 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409354 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $67.50 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409360 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $411.75 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409364 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,500.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409368 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $741.10 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409382 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.45 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409384 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $405.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409410 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,329.64 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409420 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $324.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409424 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $67.50 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409436 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,000.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409444 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $837.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409456 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $371.25 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409466 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,350.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409486 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.45 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409488 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $67.50 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409506 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,600.00 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409520 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.45 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409526 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.45 | 08/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409530 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 08/13/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184227563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 08/13/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184227601 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 08/13/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184227627 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,566.00 | 08/08/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644582 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225162 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225164 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225166 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225168 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225170 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225172 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225174 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225176 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225178 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225180 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225182 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225184 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225186 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225188 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $56.70 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225190 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225192 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $56.70 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225214 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225216 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225218 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225220 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225222 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225224 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225226 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225228 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225230 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225232 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225234 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225236 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225238 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225240 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225256 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225258 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225260 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225262 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225264 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225266 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225304 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225306 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225308 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225334 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225336 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225338 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225340 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225372 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225374 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225376 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225378 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225412 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225414 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225416 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225456 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225458 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225460 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225462 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225498 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225500 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225502 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225504 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225506 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225508 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225510 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225512 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225514 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225516 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225518 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225520 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225536 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225538 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225540 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225542 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225544 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225546 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225548 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225550 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225552 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225554 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225556 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225558 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225560 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225562 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225564 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225566 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225583 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225585 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225587 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225589 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225591 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225593 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225595 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225597 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225599 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225601 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225603 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225605 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225607 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225609 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225611 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225613 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225615 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225617 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225619 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225621 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225623 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225625 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225627 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225629 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225631 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225633 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225635 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225637 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225639 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225641 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225651 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225653 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225655 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225657 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225659 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225661 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225663 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225665 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225667 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225753 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225755 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225769 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225771 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225773 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225775 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225777 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225779 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225781 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225783 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225785 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225787 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225789 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225791 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225793 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225795 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225797 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184225799 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224064 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224066 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224096 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224098 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224100 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,120.85 | 08/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224102 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224104 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224106 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224108 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,793.15 | 08/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224130 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224132 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,793.15 | 08/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224136 |
| Principal investigator 1 | Genentech, Inc. | $1,796.00 | 08/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644286 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $55.72 | 07/30/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225408676 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,680.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222146 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $504.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222148 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $882.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222150 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $474.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222152 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,205.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222154 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $720.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222156 |
| Principal investigator 1 | Genentech, Inc. | $3,120.00 | 07/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211645067 |
| Principal investigator 1 | Genentech, Inc. | $26,279.59 | 07/29/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211645079 |
| Principal investigator 1 | Genentech, Inc. | $34,472.00 | 07/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211645347 |
| Principal investigator 1 | Roche TCRC, Inc. | $7,849.70 | 07/28/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644586 |
| Principal investigator 1 | Genentech, Inc. | $1,899.00 | 07/25/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644305 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $881.65 | 07/25/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218968 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218970 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218972 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218974 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 07/25/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218976 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218978 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 07/25/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218980 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218982 |
| Principal investigator 1 | Roche TCRC, Inc. | $18,658.32 | 07/24/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644589 |
| Principal investigator 1 | Genentech, Inc. | $12,405.00 | 07/18/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644297 |
| Principal investigator 1 | Genentech, Inc. | $898.00 | 07/18/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644301 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 07/16/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353617 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 07/16/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353619 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 07/16/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353621 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 07/16/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353623 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 07/16/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353625 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 07/16/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353627 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 07/16/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353629 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 07/16/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353631 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 07/16/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353633 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 07/16/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353635 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 07/16/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353637 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215680 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215684 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 07/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215686 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215688 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215692 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 07/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215694 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 07/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215698 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,564.00 | 07/11/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175401439 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,530.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213610 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213612 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213614 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213616 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213618 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213620 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213622 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213624 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213626 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213628 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213630 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213632 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213634 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213636 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213638 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213640 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $49.56 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213642 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $49.56 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213644 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213646 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,152.90 | 07/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213648 |
| Principal investigator 1 | Genentech, Inc. | $19,636.00 | 07/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS | OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD | No dispute reported | 06/30/2026 | 1211644744 |
| Principal investigator 1 | Genentech, Inc. | $12,722.00 | 07/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211645075 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,052.00 | 07/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242353017 |
| Principal investigator 1 | Janssen Research & Development, LLC | $86.00 | 07/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175401452 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $357.75 | 06/30/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225407860 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $82.19 | 06/30/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225407886 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $156.60 | 06/30/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225408274 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $67.50 | 06/30/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225408474 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $156.60 | 06/30/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225408476 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $357.75 | 06/30/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225408520 |
| Recipient | Ocular Therapeutix, Inc. | $9,273.37 | 06/30/2025 | Covered Recipient Physician | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250229224 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184210982 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $155.00 | 06/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184210998 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.00 | 06/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211038 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84.00 | 06/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211499 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211569 |
| Principal investigator 1 | Roche TCRC, Inc. | $976.00 | 06/26/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644534 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,210.84 | 06/26/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644543 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,750.00 | 06/26/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644551 |
| Principal investigator 1 | Roche TCRC, Inc. | $9,080.00 | 06/26/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME | No dispute reported | 06/30/2026 | 1211644561 |
| Principal investigator 1 | Roche TCRC, Inc. | $5,500.00 | 06/26/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME | No dispute reported | 06/30/2026 | 1211644564 |
| Principal investigator 1 | Roche TCRC, Inc. | $232.00 | 06/26/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644575 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $33.43 | 06/20/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225408082 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $357.75 | 06/20/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225408160 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $156.60 | 06/20/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225408212 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $474.00 | 06/18/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184207777 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $504.00 | 06/18/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184207827 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $720.00 | 06/18/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184207919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $882.00 | 06/18/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184208039 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 06/18/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184208083 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,680.00 | 06/18/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184208589 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 06/18/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184208745 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,300.00 | 06/18/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184208819 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/18/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184208931 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $200.00 | 06/11/2025 | Non-covered Recipient Entity Retina Consultants of Houston, PLLC | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250363684 |
| Principal investigator 1 | Roche TCRC, Inc. | $5,500.00 | 06/10/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME | No dispute reported | 06/30/2026 | 1211644538 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,425.00 | 06/10/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644568 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,651.00 | 06/09/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME | No dispute reported | 06/30/2026 | 1211644546 |
| Principal investigator 1 | Roche TCRC, Inc. | $17,695.00 | 06/09/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME | No dispute reported | 06/30/2026 | 1211644549 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,339.00 | 06/09/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644579 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,225.00 | 06/06/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175401417 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $156.60 | 05/28/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225407578 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $357.75 | 05/28/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225407668 |
| Principal investigator 1 | Genentech, Inc. | $65.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644243 |
| Principal investigator 1 | Genentech, Inc. | $898.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644252 |
| Principal investigator 1 | Genentech, Inc. | $957.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644271 |
| Principal investigator 1 | Genentech, Inc. | $898.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644279 |
| Principal investigator 1 | Genentech, Inc. | $1,910.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644283 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199405 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199407 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199409 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199411 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199413 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199415 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199417 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199419 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199421 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199423 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199425 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199427 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199431 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199433 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199435 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199437 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199439 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199441 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199443 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199445 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199447 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199449 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199451 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199453 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199455 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199459 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199461 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199463 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199465 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199467 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199471 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199473 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199475 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199477 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199479 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199481 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199483 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199485 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199487 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199489 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199491 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199493 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199495 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199497 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199499 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199501 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199503 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199507 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199509 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199511 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199513 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199515 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199517 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199519 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 05/28/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199521 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 05/16/2025 | Non-covered Recipient Entity Retina Consultants of Houston, PLLC | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250363686 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 05/16/2025 | Non-covered Recipient Entity Retina Consultants of Houston, PLLC | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250363688 |
| Principal investigator 1 | Roche TCRC, Inc. | $8,000.00 | 05/13/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211644697 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,440.00 | 05/08/2025 | Non-covered Recipient Entity Retina Consultants Of Houston Pllc | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | No dispute reported | 06/30/2026 | 1175282361 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,028.80 | 05/08/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644530 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346767 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346769 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $89.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346809 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346811 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346813 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346815 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346817 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346819 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346821 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346823 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346867 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346869 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346871 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346873 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346875 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346877 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346879 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346917 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346919 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346921 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346923 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346925 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 05/07/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242346927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $62.52 | 05/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184193191 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $49.56 | 05/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184193193 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $51.92 | 05/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184193195 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $61.90 | 05/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184193197 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $64.35 | 05/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184193199 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192343 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192345 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192347 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192349 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192351 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192353 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192355 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192357 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192359 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192361 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38.66 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192363 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192365 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192367 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192369 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192371 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192373 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192375 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $59.87 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192377 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192379 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192381 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192383 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192385 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192387 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192389 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192391 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192393 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192395 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192397 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192399 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192401 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192403 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192405 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192407 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192409 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192411 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192413 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $65.05 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192415 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $89.65 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192417 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192419 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192421 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192423 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192425 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192427 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192431 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192433 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192435 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192437 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192439 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192441 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192443 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192445 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.88 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192447 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192449 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192451 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192453 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192455 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192459 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192461 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192463 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $48.94 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192465 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192467 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $60.99 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192471 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192473 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192475 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192477 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192479 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192481 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192483 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184192485 |
| Principal investigator 1 | Genentech, Inc. | $10,759.00 | 05/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644255 |
| Principal investigator 1 | Genentech, Inc. | $5,335.00 | 05/01/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644266 |
| Principal investigator 1 | Roche TCRC, Inc. | $9,200.00 | 05/01/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211644708 |
| Principal investigator 1 | Roche TCRC, Inc. | $7,413.20 | 04/30/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644557 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,850.15 | 04/28/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405882 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187509 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187511 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187513 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187515 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187517 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187519 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187527 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187529 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187531 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187535 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187537 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187539 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187541 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187553 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187555 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187557 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187559 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187561 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187565 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187567 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187569 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184187571 |
| Principal investigator 1 | Roche TCRC, Inc. | $4,229.00 | 04/18/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211644701 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 04/16/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184183556 |
| Principal investigator 1 | Roche TCRC, Inc. | $6,155.50 | 04/15/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211644693 |
| Principal investigator 1 | Roche TCRC, Inc. | $12,032.00 | 04/11/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644554 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,886.00 | 04/11/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644571 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 04/04/2025 | Non-covered Recipient Entity BRAZOS RETINA CONSULTING, LLC | CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy | No dispute reported | 06/30/2026 | 1220771303 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,000.00 | 04/03/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225402979 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 04/03/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225404445 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 04/03/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225404447 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 04/03/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225404794 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,800.00 | 04/03/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225406212 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,000.00 | 04/03/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225406852 |
| Principal investigator 1 | Roche TCRC, Inc. | $4,864.00 | 04/03/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644704 |
| Principal investigator 1 | Roche TCRC, Inc. | $110.09 | 04/03/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644713 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,500.00 | 04/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184181052 |
| Principal investigator 1 | Roche TCRC, Inc. | $35,908.64 | 03/31/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644520 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179288 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179290 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179292 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179294 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179296 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179298 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179300 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179302 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179304 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179306 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179308 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179310 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179312 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179314 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179316 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179318 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179352 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179354 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179356 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179358 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179360 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179362 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179364 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179366 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179368 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179370 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179428 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179450 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179462 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179464 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179466 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179468 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179470 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179472 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179474 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179476 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179478 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179480 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179482 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179484 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179486 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179488 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179614 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179616 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179618 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179620 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179622 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179624 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179626 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179628 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179630 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179632 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179634 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179636 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179638 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179640 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179642 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179644 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179646 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179648 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179650 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179652 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179654 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179656 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179658 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179660 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179662 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179664 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179666 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179668 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179670 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179672 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179674 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179680 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179682 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179684 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179686 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179688 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179690 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179692 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179694 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179696 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179698 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179700 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179702 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179704 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179706 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179708 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179710 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179740 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179742 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179744 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179746 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179748 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179750 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179752 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179754 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179756 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179758 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179760 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179762 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179764 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179766 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179768 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179770 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179804 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179806 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179808 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179810 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179812 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179814 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179816 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179818 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179820 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179822 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179824 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179826 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179828 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179830 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179832 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179834 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179844 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179854 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179856 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179858 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179860 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179862 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179864 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179866 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179868 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179870 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179872 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179874 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179876 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179878 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179880 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179882 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179926 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179928 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179930 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179932 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179950 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179966 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179968 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179970 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179972 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179974 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179976 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179978 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179980 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179982 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179984 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184179986 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180166 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180168 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180170 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180172 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180174 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180176 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180178 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180180 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180182 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180184 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180186 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180188 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180190 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180192 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180194 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/26/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184180196 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $156.60 | 03/25/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225403327 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $357.75 | 03/25/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405892 |
| Principal investigator 1 | Roche TCRC, Inc. | $26,748.00 | 03/25/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644527 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 03/24/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225404054 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184175758 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184175760 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184175762 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184175764 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184175766 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176422 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176518 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176520 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176522 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176524 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176526 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176528 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176530 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176532 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176534 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176536 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176538 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176540 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176542 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176544 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176546 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176548 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176592 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176594 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176596 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176598 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176600 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176602 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176604 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176606 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176608 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176610 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176612 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176614 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176616 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176618 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176620 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176622 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176656 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176658 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176660 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176662 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176664 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176666 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176668 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176670 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176672 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176674 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176676 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176678 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176680 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176682 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176684 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/20/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184176686 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $53.59 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174792 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $73.61 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174794 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.39 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174796 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.10 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174798 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $71.92 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174800 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.91 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174802 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $92.87 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174804 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $82.88 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174806 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $108.87 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174808 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.82 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174810 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.96 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174812 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $145.95 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174814 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $56.08 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174816 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $75.58 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174818 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $58.88 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174820 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.23 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174822 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $60.88 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174824 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $60.66 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174826 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.89 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174828 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $102.61 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174830 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $46.76 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174832 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $53.88 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174834 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $93.56 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174836 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $66.89 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174838 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $70.95 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174840 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22.85 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174842 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.91 | 03/19/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184174844 |
| Principal investigator 1 | Roche TCRC, Inc. | $9,898.80 | 03/19/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644493 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336599 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336601 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336603 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336605 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336607 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336609 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336611 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336713 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336715 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336717 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336719 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336721 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336723 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336725 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336727 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336823 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336825 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336827 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,846.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336829 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,493.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336831 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,466.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242336833 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337507 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337509 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337567 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337569 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337643 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,775.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337645 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $108.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337647 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337649 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $89.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337651 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.00 | 03/12/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242337797 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171590 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171592 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171596 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171598 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171600 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171602 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171604 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171606 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171608 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171610 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171612 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171614 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171618 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171620 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171622 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171692 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171694 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171696 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171698 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171700 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171702 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171704 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171706 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171708 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171710 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171712 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171714 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171716 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171718 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171720 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171722 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171788 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171790 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171792 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171794 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171796 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171798 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171800 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171802 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171804 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171806 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171808 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171810 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171812 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171814 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171816 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171818 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171884 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171886 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171888 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171890 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171892 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171894 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171896 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171898 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171900 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171902 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171904 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171906 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171908 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171910 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171912 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171914 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171980 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171982 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171984 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171986 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171988 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171990 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171992 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171994 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171996 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184171998 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172000 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172002 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172004 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172006 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172008 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172010 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172076 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172078 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172080 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172082 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172084 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172086 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172088 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172090 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172092 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172094 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172096 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172098 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172100 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172102 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172104 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172106 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172148 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172150 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172152 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172154 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172156 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172158 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172160 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172162 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172164 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172166 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172168 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172170 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172172 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172174 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172176 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172178 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172200 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172202 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172204 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172206 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172208 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172210 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172212 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172214 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172216 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172218 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172220 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172222 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172224 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 03/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172226 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,310.00 | 03/11/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME | No dispute reported | 06/30/2026 | 1211644489 |
| Principal investigator 1 | Roche TCRC, Inc. | $537.00 | 03/10/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644524 |
| Principal investigator 1 | Genentech, Inc. | $4,610.00 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644232 |
| Principal investigator 1 | Genentech, Inc. | $65.00 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644236 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $172.06 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159607 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159613 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $172.06 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159617 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $299.57 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159641 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $337.22 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159663 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $352.36 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.23 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159673 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $445.49 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159683 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $378.68 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159705 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159709 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159711 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $312.25 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159713 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $445.49 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159715 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $299.57 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159719 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159721 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $367.33 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184159723 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $352.36 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160033 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $364.91 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160035 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.23 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160037 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $294.98 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160039 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $378.68 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160041 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160043 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160045 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $369.22 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160047 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $319.82 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160049 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160051 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $364.91 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160053 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160055 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $367.33 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160057 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $312.25 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160059 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160061 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $363.02 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160063 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.52 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160065 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $363.02 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160067 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $258.40 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160077 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $217.90 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160085 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $337.22 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160109 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160115 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $363.02 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160123 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160145 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160167 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $299.57 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160189 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $294.98 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160211 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $337.22 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160223 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160245 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160267 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $445.49 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160281 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160283 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184160345 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $378.68 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162065 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162366 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162368 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $299.57 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162374 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.52 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162376 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $194.94 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162378 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $258.40 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162380 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $217.90 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162382 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $337.22 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162384 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162386 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162388 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $445.49 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162390 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $319.82 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162392 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $337.22 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162396 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $312.25 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162398 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $367.33 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162400 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162402 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $352.36 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162736 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $364.91 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162738 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162740 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162742 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162744 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.23 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162746 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $294.98 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162748 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $378.68 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162750 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162752 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162754 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162758 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $352.36 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162760 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $364.91 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162762 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162764 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162766 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $319.82 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184162768 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $364.91 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163088 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163090 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163092 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $364.91 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163094 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163096 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163098 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.23 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163100 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $378.68 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163102 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $352.36 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163104 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163106 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163108 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $369.22 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163110 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $319.82 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163112 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $262.70 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163114 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $312.25 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163116 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $299.57 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163118 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $367.33 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163156 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163166 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163188 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $337.22 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163210 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163232 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $363.02 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163234 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163246 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $194.94 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163268 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163290 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $369.22 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163312 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $319.82 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163316 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $337.22 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163320 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $262.70 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163328 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163350 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $352.36 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163372 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.23 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184163390 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $294.98 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166581 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166599 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166601 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.23 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166603 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $294.98 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166605 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $378.68 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166607 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166609 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166613 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $369.22 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166621 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166629 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $445.49 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166651 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $299.57 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166673 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166693 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166695 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166705 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $352.36 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184166727 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $364.91 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169332 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169334 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169336 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $364.91 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169356 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169374 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169386 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.23 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169408 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $294.98 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169428 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $378.68 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169430 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169438 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $301.46 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169460 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $369.22 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169464 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $319.82 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169472 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $312.25 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169494 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $294.98 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169518 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $299.57 | 03/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184169540 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36.00 | 03/06/2025 | Non-covered Recipient Entity Retina Consultants Of Houston Pllc | Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | No dispute reported | 06/30/2026 | 1175282677 |
| Principal investigator 1 | Roche TCRC, Inc. | $76,292.82 | 03/06/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644496 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $49.56 | 03/05/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156961 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $49.56 | 03/05/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156963 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $49.56 | 03/05/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156965 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,624.15 | 03/05/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156967 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $761.50 | 03/05/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156969 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333270 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333274 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333276 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333278 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333280 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333300 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,623.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333302 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333304 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333306 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333308 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333310 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333312 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,835.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333314 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333316 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,958.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333318 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333320 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333322 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333324 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333326 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333328 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333330 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333332 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333338 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,493.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333340 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333342 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,466.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333346 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,846.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333348 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,623.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333350 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,958.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333352 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,493.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333356 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,466.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333358 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,156.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333360 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,623.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333362 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,958.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242333364 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242334594 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242334596 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242334598 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 03/03/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242334600 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 02/28/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225403867 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 02/28/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405002 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 02/28/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405884 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,631.27 | 02/27/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225403235 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,271.27 | 02/27/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1225406906 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 02/27/2025 | Non-covered Recipient Entity Retina Consultants Of Houston Pllc | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | No dispute reported | 06/30/2026 | 1175281562 |
| Principal investigator 1 | Roche TCRC, Inc. | $350.00 | 02/21/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644679 |
| Principal investigator 1 | Roche TCRC, Inc. | $9,874.73 | 02/20/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644469 |
| Principal investigator 1 | Roche TCRC, Inc. | $77,092.48 | 02/19/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644473 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 02/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston Pllc | Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | No dispute reported | 06/30/2026 | 1175281764 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,290.00 | 02/13/2025 | Non-covered Recipient Entity Retina Consultants Of Houston Pllc | Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | No dispute reported | 06/30/2026 | 1175282010 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $77,735.70 | 02/12/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) | No dispute reported | 06/30/2026 | 1185550942 |
| Principal investigator 1 | Roche TCRC, Inc. | $748.00 | 02/12/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644461 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,652.90 | 02/12/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644477 |
| Principal investigator 1 | Roche TCRC, Inc. | $250.00 | 02/12/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644485 |
| Principal investigator 1 | Roche TCRC, Inc. | $429.00 | 02/12/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644499 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,847.71 | 02/12/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644507 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,666.80 | 02/11/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644689 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,467.05 | 02/07/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236769 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,850.15 | 01/30/2025 | Non-covered Recipient Entity Retina Consultants Of Houston PA-Bellaire | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225404052 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $80,078.90 | 01/30/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS | A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1190300529 |
| Principal investigator 1 | Roche TCRC, Inc. | $428.00 | 01/27/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644464 |
| Principal investigator 1 | Genentech, Inc. | $11,898.00 | 01/24/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644223 |
| Principal investigator 1 | Roche TCRC, Inc. | $421.75 | 01/24/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211644676 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328965 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,835.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328967 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328969 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328971 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242328973 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,835.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329037 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329039 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329041 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329043 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329045 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329047 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,835.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329049 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329051 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329119 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329121 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329123 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329125 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329127 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329193 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329195 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329197 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,775.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329199 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329201 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $89.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329203 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329205 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329207 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329267 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329269 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329271 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329273 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329275 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329277 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329279 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329349 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329351 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329353 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329355 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329357 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329359 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329361 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329363 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,761.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329421 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,493.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329423 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,466.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329425 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,156.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329427 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,846.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329429 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,156.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329431 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.00 | 01/22/2025 | Non-covered Recipient Entity COMMUNITY CLINICAL RESEARCH INC | ITI-007-451 | No dispute reported | 06/30/2026 | 1242329433 |
| Principal investigator 1 | Roche TCRC, Inc. | $37,182.00 | 01/21/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644480 |
| Principal investigator 1 | Roche TCRC, Inc. | $30,483.00 | 01/21/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644503 |
| Principal investigator 1 | Roche TCRC, Inc. | $4,734.59 | 01/21/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644515 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 01/17/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184148337 |
| Principal investigator 1 | Roche TCRC, Inc. | $6,369.06 | 01/14/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644510 |
| Principal investigator 1 | Roche TCRC, Inc. | $7,784.00 | 01/14/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211644673 |
| Principal investigator 1 | Genentech, Inc. | $7,118.00 | 01/10/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211644240 |
| Principal investigator 1 | Janssen Research & Development, LLC | $86.00 | 01/09/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF HOUSTON PLLC | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175401546 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146823 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146825 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146827 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146829 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146831 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146835 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146837 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146839 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146841 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146843 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146845 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146847 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146849 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146851 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146853 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146855 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146857 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146859 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146861 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146863 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146865 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146867 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146869 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146871 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146873 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146875 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146877 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146879 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146881 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146883 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146885 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146887 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146889 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146891 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146893 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146895 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146897 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146899 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146901 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146903 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146905 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146909 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146911 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146913 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146915 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146917 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146923 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146925 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146929 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146931 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146933 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146935 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146937 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146939 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146941 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146943 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146945 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146947 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146949 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146951 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146953 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146955 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146957 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146959 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146961 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146963 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146965 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146967 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146969 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 01/08/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184146971 |
| Principal investigator 1 | Roche TCRC, Inc. | $12,652.35 | 01/07/2025 | Non-covered Recipient Entity Retina Consultants of Houston d/b/a Retina Consultants of Texas | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211644684 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $103,743.77 | 01/06/2025 | Non-covered Recipient Entity Community Clinical Research | A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) | No dispute reported | 06/30/2026 | 1235997866 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,228,826.68 | 01/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1190311249 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $761.50 | 01/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184144520 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,132.75 | 01/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184144522 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,132.75 | 01/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184144524 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 01/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184144526 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,132.75 | 01/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184144528 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,267.75 | 01/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184144530 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,132.75 | 01/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184144532 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $761.50 | 01/02/2025 | Non-covered Recipient Entity RETINA CONSULTANTS OF TEXAS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184144534 |